- 10th International Peptide Symposium and 55th Japanese Peptide Symposium
10th International Peptide Symposium and 55th Japanese Peptide Symposium
ROHM Theatre Kyoto
13 Okazaki Saishōjichō
Sakyō-ku, Kyōto-shi, Kyōto-fu 606-8342
December 3, 2018 – December 7, 2018
- Welcome to the new PurePEG
We have redesigned our website to better suit client needs! Please take a look around and browse our new and expanded catalog.
For all new and existing PurePEG clients, I invite you to save 15% off your next order by completing a short survey in regards to our new website. Please follow the link below and complete the survey in order to receive your 15% off coupon code!
The PurePEG Team
- 256th ACS National Meeting & Exposition
256th ACS National Meeting & Exposition
415 Summer St. – Boston
Aug 19, 2018 – Aug 23, 2018
- PEGylated dendrimers: a new way to deliver drugs
Our researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd (ASX:SPL), have developed a new drug delivery method that could benefit thousands of patients worldwide with particular types of cancer, HIV and lymphatic conditions.
The Melbourne-based research team has shown how PEGylated polylysine dendrimers, a new type of nanosized drug delivery system, can be altered to target either the lymphatic system or the bloodstream.
Lead researcher at the Monash Institute of Pharmaceutical Sciences and Associate Dean of Research, Professor Chris Porter, said the discovery has particular implications for the treatment of diseases that are spread via thelymphatics and lymph nodes.
“We are excited by the possibilities that this technology may result the improved treatment of particular types of diseases, including metastatic cancer, lymphoma, HIV and metastitial tuberculosis,” Professor Porter said.
Dendrimers are precisely defined, synthetic nanomaterials of approximately five to 10 nanometres in diameter. They consist of layers of polymer surrounding a central core.
The dendrimer surface contains many different sites to which drugs may be attached as well as attachment sites for materials such as polyethylene glycol (PEG), which can be used to modify the way the dendrimer interacts with the body.
PEG can be attached to the dendrimer to ‘disguise’ it and prevent the body’s defence mechanisms detecting it, slowing the breakdown process. This allows the delivery system to circulate in the body for an extended period, maximising opportunities for the drug to reach the relevant sites.
Professor Porter’s group and Starpharma have been investigating dendrimer-based drug delivery systems for some time, but these most recent findings appear to hold particular promise.
The data, published in the Journal of Controlled Release, demonstrate that increasing the chain length of attached PEG chains to increase dendrimer size can achieve a dramatic rise in absorption efficiency and transport into the lymphatic system after subcutaneous injection. Conversely, a shorter PEG chain led to rapid absorption into the blood.
“Our work suggests that careful design of the size and surface characteristics of PEGylated polylysine dendrimers provides an opportunity to choose whether these delivery systems are absorbed and distributed via the bloodstream or the lymphatic system,” Professor Porter said.
“The ability to target therapeutic treatments in this way offers the potential to maximise drug concentrations at sites of action within the lymphatic system – and importantly to minimise concentrations elsewhere, potentially reducing side effects and toxicity. It’s still early days, but we’re confident the potential for improved patient treatment is significant.”
- Drug Delivery Modification Sidesteps Allergic Responses
Biomedical engineers at Duke University have reconfigured a popular drug-delivery technology to evade immune responses that have halted some clinical trials.
Polyethylene glycol, commonly known as PEG, is a polymer commonly found in commercial products from toothpaste to cosmetics, and also in pharmaceuticals. PEG is used as a thickener, solvent, softener and moisture-carrier, but it can also be attached to active drugs in the bloodstream to slow the body’s clearing of them, greatly lengthening the duration of their effects.
The pervasiveness of PEG in daily human life, however, is causing many people to develop antibodies to the polymer. This has led some PEG-modified or “PEGylated” drugs to lose their longevity and has caused allergic reactions, some of which have been life-threatening.
In a new paper, Duke researchers reveal an altered version of PEG that seems to avoid recognition by PEG antibodies already present in individuals. The new technology also shows excellent efficacy, controlling glucose levels in diabetic mice for up to 4 days when used with a drug that, without PEG, treats type 2 diabetes for just six hours.
The results appeared online on November 28, 2016, in the new journal Nature Biomedical Engineering.
“This work has been an interesting journey with the unexpected twists and turns that makes research so rewarding,” said Ashutosh Chilkoti, the Alan L. Kaganov Professor of Biomedical Engineering and chair of the biomedical engineering department.
“We started down a path to make PEG-like conjugates of protein drugs more efficiently and stumbled into the PEG antigenicity problem,” Chilkoti said. “We were lucky to find an expert close at hand in the School of Medicine at Duke. This work was only possible because of the incredible interdisciplinary research culture at Duke that recognizes no boundaries.”
The new PEG delivery system was initially developed by Chilkoti and graduate student Yizhi (Stacey) Qi to boost production efficiency. Conventional PEG drug-delivery polymers require labor-intensive synthesis and purification, but the new polymers are grown directly from a defined site on a drug molecule. The new polymer looks a lot like a bottle cleaning brush, with many short segments of ethylene glycol sticking out from a primary backbone.
“Growing the polymer directly on the drug is simpler and more efficient in terms of yield than the conventional process,” said Qi, who successfully defended her thesis in August. “The boost in efficiency varies from protein to protein, but our yield is significantly higher and produces more uniform results.”
Meanwhile, just a few hundred yards away, a different challenge was being faced by Bruce Sullenger, the Joseph W. and Dorothy W. Beard Professor of Experimental Surgery and director of the Duke Translational Research Institute. During a late-stage clinical trial for an anticoagulant that used PEG to extend its effectiveness, 10 patients had an immediate, anaphylactic immune reaction because of pre-existing PEG antibodies.
The clinical trials were immediately shut down.
“These allergic reactions stopped the development of an otherwise very promising approach to control blood clotting while limiting bleeding,” said Sullenger. “Because people with pre-existing PEG antibodies are now present in the population and such antibodies can elicit life-threatening allergic reactions, it has become critical for drug development to create alternative formulations of PEG.”
Chilkoti heard about this problem and thought that his lab’s new bottle-brush PEG polymer might be a solution. Because each of the molecular chain “bristles” are so short, existing PEG antibodies might not be able to recognize them.
To find out, Chilkoti and Qi turned to Michael Hershfield, professor of medicine and biochemistry at the Duke University School of Medicine. Hershfield has been involved with PEG technology ever since the clinical trials and FDA approval for the very first PEGylated drug in 1990. An immune response to this drug has never been an issue, because its intended recipients are children with deficient immune systems.
A second drug he helped develop in the early 2000s to treat gout, however, has encountered obstacles. About 40 percent of patients develop antibodies to the PEG portion of the drug after the first few doses, leading to allergic reactions and a loss of effectiveness.
“Nancy Ganson, a scientist in my lab, and I got involved with Professor Chilkoti’s project because we had discovered that anti-PEG antibodies were induced by our PEGylated gout drug during clinical trials” said Hershfield. “We later identified high levels of pre-existing anti-PEG antibodies in the first three patients who had allergic reactions to Dr. Sullenger’s PEGylated anticoagulant. Professor Chilkoti’s initial substitute for PEG still had a little bit of PEG on it, so we needed to see if anti-PEG antibodies could recognize it.”
On their second try at designing a suitable PEG substitute, the team hit pay dirt. The antibodies left the new compound alone.
Qi then attached her new polymer to a drug used to treat type 2 diabetes and injected it into diabetic mice to see if the system still worked as well. To her delight, there was almost no loss of efficacy, extending the effects of one drug 16-fold.
With this success in hand, the team next plans to test for immunological responses in living animals with preexisting PEG antibodies. They also need to determine whether antibodies will be created against the new polymers.
This work was supported by the National Institutes of Health (R01-DK092665).
CITATION: “A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity.” Yizhi Qi, Antonina Simakova, Nancy J. Ganson, Xinghai Li, Kelli M. Luginbuhl, Imran Ozer, Wenge Liu, Michael S. Hershfield, Krzysztof Matyjaszewski, Ashutosh Chilkoti. Nature Biomedical Engineering. Nov. 28, 2016. DOI: 10.1038/s41551-016-0002 http://www.nature.com/articles/s41551-016-0002
Monodisperse PurePEG Reagents for Biomedical Applications.